14 articles for thisTarget

---

The following articles (labelled with PubMed ID or TBD) are for your review

PMID	Data	Article Title	Organization
25874340	37	Novel imidazole derivatives as heme oxygenase-1 (HO-1) and heme oxygenase-2 (HO-2) inhibitors and their cytotoxic activity in human-derived cancer cell lines.	University of Catania
24021581	72	Selective inhibition of heme oxygenase-2 activity by analogs of 1-(4-chlorobenzyl)-2-(pyrrolidin-1-ylmethyl)-1H-benzimidazole (clemizole): Exploration of the effects of substituents at the N-1 position.	Queen'S University
23867390	37	Evaluation of novel aryloxyalkyl derivatives of imidazole and 1,2,4-triazole as heme oxygenase-1 (HO-1) inhibitors and their antitumor properties.	University of Catania
17339115	32	Heme oxygenase inhibition by 2-oxy-substituted 1-(1H-imidazol-1-yl)-4-phenylbutanes: effect of halogen substitution in the phenyl ring.	Queen'S University
16821802	30	Imidazole-dioxolane compounds as isozyme-selective heme oxygenase inhibitors.	Queen'S University
18798608	3	X-ray crystal structure of human heme oxygenase-1 in complex with 1-(adamantan-1-yl)-2-(1H-imidazol-1-yl)ethanone: a common binding mode for imidazole-based heme oxygenase-1 inhibitors.	Queen'S University
15713406	22	Synthesis and evaluation of azalanstat analogues as heme oxygenase inhibitors.	Queen'S University
30784878	40	Progress in the development of selective heme oxygenase-1 inhibitors and their potential therapeutic application.	University of Catania
31550661	74	Heme Oxygenase-2 (HO-2) as a therapeutic target: Activators and inhibitors.	University of Catania
30261468	20	Targeting heme Oxygenase-1 with hybrid compounds to overcome Imatinib resistance in chronic myeloid leukemia cell lines.	University of Catania
29454190	44	Potholing of the hydrophobic heme oxygenase-1 western region for the search of potent and selective imidazole-based inhibitors.	University of Catania
10336515	3	Pharmacological properties of J-104132 (L-753,037), a potent, orally active, mixed ETA/ETB endothelin receptor antagonist.	Banyu Pharmaceutical
10215672	11	Receptor binding, behavioral, and electrophysiological profiles of nonpeptide corticotropin-releasing factor subtype 1 receptor antagonists CRA1000 and CRA1001.	Taisho Pharmaceutical